Ondine Biomedical (LON:OBI) Hits New 1-Year Low – Time to Sell?

Ondine Biomedical Inc. (LON:OBI)’s stock price hit a new 52-week low on Thursday . The company traded as low as C$7.50 and last traded at C$8.00, with a volume of 89210 shares traded. The stock had previously closed at C$8.00.

Ondine Biomedical Trading Up 6.0%

The business’s 50 day simple moving average is C$9.66 and its 200 day simple moving average is C$12.50. The company has a debt-to-equity ratio of 25.95, a current ratio of 1.36 and a quick ratio of 8.26. The company has a market capitalization of C$4.53 billion, a price-to-earnings ratio of -1.25 and a beta of 0.10.

About Ondine Biomedical

Ondine Biomedical is a life sciences company leading the charge in breakthrough photodisinfection-based therapies to prevent and treat serious infections, including those caused by existing, emerging, and antimicrobial-resistant pathogens.

Our vision is a world free from infections. We have created a patented, platform technology (photodisinfection) to provide simple solutions to complex infections across different therapeutic areas in healthcare and industry settings. We are focused on solutions that address significant needs, are easy to deploy, are environmentally safe, provide substantial public health benefits, and cost a fraction of the infections they target.

Our photodisinfection technology has been used successfully for many years in more than 100,000 patient treatments in hospitals, clinics, and industrial settings across Canada.